Yes. It's product positioning. The firm that can offer regular and VLN cigs and vape/alt tech will be in the best position in the market. Waiting to see which Big T has the vision to be proactive versus waiting for a mandate
...by suggesting least likely to do harm, after mandating VLN in general.
As I have said all along...FDA will likely to be mandate VLN "SOME TIME IN THE FUTURE"...but not all VLN roads lead to XXII. A bounce from VLN nicotine factor will come, (how great is anyone's guess) when it is clear FDA is ready to implement or BT steps into XXII's office ready to execute a licensing agreement.
ps. Still flat...IMHO...not compelling enough to step in yet.